Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Pipeline Review, H1 2018

Publisher Name :
Date: 12-Jun-2018
No. of pages: 44

Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Pipeline Review, H1 2018

Summary

According to the recently published report 'SerineThreonine Protein Kinase ATR - Pipeline Review, H1 2018'; Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.

Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Serine/threonine-protein kinase ATR is an enzyme encoded by the ATR gene. It is required for cell cycle arrest and DNA damage repair in response to DNA damage. It has shown to phosphorylate checkpoint kinase CHK1, checkpoint proteins RAD17, and RAD9, as well as tumor suppressor protein BRCA1.

The report 'SerineThreonine Protein Kinase ATR - Pipeline Review, H1 2018' outlays comprehensive information on the Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 4 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively.

Report covers products from therapy areas Oncology which include indications Ovarian Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Breast Cancer, Fallopian Tube Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Lung Adenocarcinoma, Metastatic Breast Cancer, Peritoneal Cancer, Small-Cell Lung Cancer, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Cervical Cancer, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Lymphoma, Mantle Cell Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Ovarian Cancer, Neuroendocrine Tumors, Non-Hodgkin Lymphoma, Pancreatic Cancer, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Squamous Cell Carcinoma and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1)

- The report reviews Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

- The report assesses Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Pipeline Review, H1 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Overview
Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Companies Involved in Therapeutics Development
AstraZeneca Plc
Bayer AG
Biokine Therapeutics Ltd
Merck KGaA
Pfizer Inc
Vertex Pharmaceuticals Inc
Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Drug Profiles
ATRN-119 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZ-20 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-6738 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-6738 + olaparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1895344 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
berzosertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BKT-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-4344 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ATR for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ATR for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VE-821 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Dormant Products
Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
May 16, 2018: Merck's M6620 Data at ASCO 2018 to Showcase Progress and Further Optionality of Oncology Pipeline
Aug 30, 2017: Merck To Present Data On M6620 At ESMO 2017
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by AstraZeneca Plc, H1 2018
Pipeline by Bayer AG, H1 2018
Pipeline by Biokine Therapeutics Ltd, H1 2018
Pipeline by Merck KGaA, H1 2018
Pipeline by Pfizer Inc, H1 2018
Pipeline by Vertex Pharmaceuticals Inc, H1 2018
Dormant Projects, H1 2018

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
  • Global Epoprostenol Sodium Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 18-Jan-2019        Price: US 3480 Onwards        Pages: 102
    It is solid powder and used primarily for the treatment of pulmonary hypertension. Scope of the Report: The worldwide market for Epoprostenol Sodium is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study. This report focuses on the Epoprostenol Sodium in global market, especially in North America, Europe and Asia-Pacific, South America,......
  • Global Tafluprost Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 18-Jan-2019        Price: US 3480 Onwards        Pages: 115
    It is an anti-glaucoma prostaglandin (PG) analog. Scope of the Report: The worldwide market for Tafluprost is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study. This report focuses on the Tafluprost in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the......
  • Global Eszopiclone Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 18-Jan-2019        Price: US 3480 Onwards        Pages: 109
    Eszopiclone is a nonbenzodiazepine hypnotic agent. Scope of the Report: The worldwide market for Eszopiclone is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study. This report focuses on the Eszopiclone in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes ......
  • Global Abthrax Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 18-Jan-2019        Price: US 3480 Onwards        Pages: 102
    Abthrax is a human monoclonal antibody intended for the prophylaxis and treatment of inhaled anthrax Scope of the Report: The worldwide market for Abthrax is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study. This report focuses on the Abthrax in global market, especially in North America, Europe and Asia-Pacific, South America, Middle......
  • Global Raxibacumab Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 18-Jan-2019        Price: US 3480 Onwards        Pages: 105
    Raxibacumab is a human monoclonal antibody intended for the prophylaxis and treatment of inhaled anthrax Scope of the Report: The worldwide market for Raxibacumab is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study. This report focuses on the Raxibacumab in global market, especially in North America, Europe and Asia-Pacific, South Ame......
  • Global Anthim Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 18-Jan-2019        Price: US 3480 Onwards        Pages: 104
    ANTHIM® (obiltoxaximab) is indicated in adult and pediatric patients for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs Scope of the Report: The worldwide market for Anthim is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study. This report focuses on the Anthim in glob......
  • Global Obiltoxaximab Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 18-Jan-2019        Price: US 3480 Onwards        Pages: 107
    ANTHIM® (obiltoxaximab) is indicated in adult and pediatric patients for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs Scope of the Report: The worldwide market for Obiltoxaximab is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study. This report focuses on the Obiltox......
  • Global Anthrasil Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 18-Jan-2019        Price: US 3480 Onwards        Pages: 105
    Anthrax immune globulin, tradename Anthrasil, is a human immune globulin that is used in combination with antibiotics to treat anthrax. Scope of the Report: The worldwide market for Anthrasil is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study. This report focuses on the Anthrasil in global market, especially in North America, Europe......
  • Global Anthrax Immune Globulin Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 18-Jan-2019        Price: US 3480 Onwards        Pages: 103
    Anthrax immune globulin, tradename Anthrasil, is a human immune globulin that is used in combination with antibiotics to treat anthrax. Scope of the Report: The worldwide market for Anthrax Immune Globulin is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study. This report focuses on the Anthrax Immune Globulin in global market, especia......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs